Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579901 | 0.85 | ALDH1A1 (0.57) | PTGESHDAC6LMNACYP1A2PTGS1 | |
| SCHEMBL30789263 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL30789261 | 0.79 | ESR1 (0.52) | LMNAMAPT | |
| SCHEMBL28021758 | 0.79 | HDAC6 (0.58) | PTGESMEN1NPC1RAB9AKMT2A | |
| SCHEMBL5579985 | 0.77 | CA1 (0.54) | MEN1NPC1RAB9AKMT2AHDAC6 | |
| SCHEMBL11326133 | 0.74 | ALDH1A1 (0.71) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL11497454 | 0.74 | PTGES (0.51) | PTGESMEN1NPC1RAB9AKMT2A | |
| SCHEMBL30789250 | 0.73 | ALDH1A1 (0.61) | MEN1KMT2ALMNACYP1A2CYP2C19 | |
| SCHEMBL30789276 | 0.73 | TP53 (0.71) | NPC1RAB9ALMNAMAPT | |
| SCHEMBL28202091 | 0.72 | RAB9A (0.50) | PTGESMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | PTGES 670/4885MEN1 3071/4885NPC1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.